Open AccessComparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study
Author(s) -
Robert Zivadinov,
Kiren Kresa-Reahl,
Bianca WeinstockGuttman,
Keith R. Edwards,
Chakkarin Burudpakdee,
Niels Bergsland,
Michael G. Dwyer,
Bhupendra Khatri,
Karthinathan Thangavelu,
Jeffrey Chavin,
Matt Mandel,
Stanley Cohan
Publication year - 2019
Publication title -
journal of comparative effectiveness research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.567
H-Index - 23
eISSN - 2042-6313
pISSN - 2042-6305
DOI - 10.2217/cer-2018-0135
Subject(s) - dimethyl fumarate , teriflunomide , medicine , multiple sclerosis , relapsing remitting , magnetic resonance imaging , nuclear medicine , glatiramer acetate , atrophy , clinical trial , radiology , immunology , fingolimod
Aim: Head-to-head clinical trials of teriflunomide (TFM) versus dimethyl fumarate (DMF) have not been conducted. Objectives: To compare the real-world effectiveness of TFM versus DMF. Methods: Anonymized data were collected from patients with relapsing multiple sclerosis (MS) initiating treatment with teriflunomide (N = 50) or DMF (N = 50). Results: On follow-up magnetic resonance imaging (MRI) compared with baseline, with TFM versus DMF treatment, the proportion of patients with new/enlarging T2 or gadolinium-enhancing lesions was 30.0 versus 40.0% (p = 0.2752). However, median annualized percent whole brain volume change was -0.1 versus -0.5 (p = 0.0212). There were no significant treatment differences on additional MRI and clinical end points and no unexpected safety signals. Conclusion: The effectiveness of teriflunomide was superior to DMF on whole brain atrophy and similar to DMF on other MRI/clinical end points.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom